“Testosterone replacement therapy is anti-aging”

## The Evidence for Hypogonadal Men In men with clinically confirmed hypogonadism (total testosterone <300 ng/dL with symptoms), TRT clearly improves: muscle mass and strength, bone mineral density, sexual function, mood, and energy. These are well-established benefits from multiple RCTs including the Testosterone Trials (TTrials, Snyder et al., *NEJM*, 2016). ## What Doesn't Translate to "Anti-Aging" Testosterone naturally declines ~1–2%/year after age 30 (late-onset hypogonadism). Whether treating this normal decline with TRT in men with mid-normal levels provides longevity benefits is unproven. The TRAVERSE trial (Lincoff et al., *NEJM*, 2023), the largest cardiovascular safety trial of TRT (5,200 men, 3.4 years), found TRT was non-inferior to placebo for cardiovascular events — but also showed higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. ## The Anti-Aging Industry Context Direct-to-consumer TRT clinics routinely prescribe testosterone to men with low-normal levels based on vague symptoms, without confirming true hypogonadism. This practice is not supported by RCT evidence for longevity benefit and carries real risks. ## Bottom Line TRT is appropriate medicine for true hypogonadism. As an "anti-aging" treatment in normal men, it has risk without proven longevity benefit.